Trial Profile

A randomized, placebo-controlled, and observer-blinded Phase IIb, multi-center clinical study of BPZE1 versus Boostrix

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 15 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BPZE 1 (Primary) ; DTaP vaccine
Indications Pertussis
Focus Adverse reactions; Pharmacodynamics
Sponsors ILiAD Biotechnologies

Most Recent Events

10 Mar 2023 According to a ILiAD Biotechnologies media release, results from this trial were published in The Lancet.
10 Mar 2023 Results published in the ILiAD Biotechnologies Media Release.
27 Jun 2022 According to a ILiAD Biotechnologies media release, data from this study will be presented at the 13th International Bordetella Symposium.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com